Immucell (ICCC) Cost of Revenue (2010 - 2026)

Immucell (ICCC) has 16 years of Cost of Revenue data on file, last reported at $4.7 million in Q4 2025.

• Quarterly Cost of Revenue fell 4.14% year-over-year to $4.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.2 million (down 12.68% YoY) and the FY2025 annual result came in at $16.2 million, down 12.68% from the prior year.
• Cost of Revenue climbed to $4.7 million in Q4 2025, from $3.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $5.0 million in Q1 2024 to a low of $2.2 million in Q2 2022.
• A 5-year average of $3.5 million and a median of $3.1 million in 2025 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue surged 70.46% — and 2025, when it declined 29.02%.
• Tracing ICCC's Cost of Revenue over 5 years: stood at $2.9 million in 2021, then gained by 1.23% to $2.9 million in 2022, then surged by 41.49% to $4.1 million in 2023, then increased by 19.13% to $4.9 million in 2024, then decreased by 4.14% to $4.7 million in 2025.
• The last three Cost of Revenue figures came in at $4.7 million (Q4 2025), $3.1 million (Q3 2025), and $3.6 million (Q2 2025), per Business Quant data.